Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Accuray Incorporated(ARAY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ARAY
09/25/2026: ARAY (1-star) is currently NOT-A-BUY. Pass it for now.
Accuray Incorporated is a specialized medical device company known for its precision radiotherapy systems, including the CyberKnife and Radixact platforms. The company maintains a leading position in robotic radiosurgery, which provides unique clinical value, though it operates in a market dominated by much larger, integrated competitors like Siemens Healthineers. Its primary growth opportunity lies in international market expansion and software-driven treatment efficiency. Investors should monitor significant competitive, execution, and operational risks, as the company frequently struggles to maintain consistent profitability. This stock may suit investors interested in niche med-tech with a high tolerance for volatility, though it is not currently a candidate for those seeking dividends or stability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Accuray offers exposure to the radiation oncology market but faces stiff competition that limits rapid scaling. |
| Momentum investor | Weak fit | The stock often lacks sustained breakout trends, making it less attractive for momentum-based strategies. |
| Value investor | Mixed fit | While the valuation can be attractive, the lack of consistent earnings makes it a difficult value play. |
| Dividend investor | Weak fit | Accuray does not pay a dividend and focuses capital on R&D and operations. |
| Low-risk investor | Weak fit | High volatility and operational uncertainty make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock's limited liquidity and market cap contribute to frequent, sharp price swings. |
| Valuation risk | Medium | Valuation is sensitive to growth projections that are not always met. |
| Competition risk (Major Players) | High | Dominant competitors with larger sales forces consistently challenge Accuray's market share. |
| Business quality | Medium | The company maintains a solid niche technology base but struggles with consistent profit margins. |
| Dividend income | Low / none | There is no dividend income available for investors. |
| Execution risk | Medium / high | Timing of equipment deliveries and global supply chain stability are critical to meeting financial targets. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -48.94% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.69M USD | Price to earnings Ratio - | 1Y Target Price 0.35 |
Price to earnings Ratio - | 1Y Target Price 0.35 | ||
Volume (30-day avg) 544.2K shares | Beta 1.39 | 52 Weeks Range 0.22 - 2.10 | Updated Date 09/25/2026 |
52 Weeks Range 0.22 - 2.10 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Sale of CyberKnife and Radixact systems. | This is the primary lump-sum revenue generated from hospital capital budget allocations. |
| Service Revenue | Maintenance contracts, software upgrades, and training. | This provides a more predictable, recurring revenue stream compared to equipment sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 94.34 | Enterprise Value 170.20M | Price to Sales(TTM) 0.06 |
Enterprise Value 170.20M | Price to Sales(TTM) 0.06 | ||
Enterprise Value to Revenue 0.42 | Enterprise Value to EBITDA 15.07 | Shares Outstanding 119.44M | Shares Floating 113.73M |
Shares Outstanding 119.44M | Shares Floating 113.73M | ||
Percent Insiders 4.36 | Percent Institutions 64.5 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Accuray Incorporated
Exchange NASDAQ | Headquarters Madison, WI, United States | ||
IPO Launch date 2007-02-08 | President, CEO & Director Mr. Stephen R. LaNeve MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 809 | Website https://www.accuray.com |
Full time employees 809 | Website https://www.accuray.com | ||
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.